We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Xpert Ultra Nasopharyngeal Swab Assessed for Identification of Tuberculosis Deaths

By LabMedica International staff writers
Posted on 21 Apr 2022

Post-mortem studies have confirmed a high prevalence of tuberculosis (TB) at autopsy in sub-Saharan Africa (sSA), in up to 43% in HIV-positive adults, and more than 30% of adults dying at home with unknown cause of death. More...

Identifying missed TB deaths is important for accurate measurement of disease burden, especially in endemic settings with limited clinical resources. Enhanced case detection by post-mortem testing would improve mortality assessments.

An international team of Infectious Diseases scientists led by Duke University (Durham, NC, USA) enrolled pediatric and adult medical deaths to a prospective autopsy study at two referral hospitals in northern Tanzania from October 2016 through May 2019. Of 205 decedents, 78 (38.0%) were female and median age was 45 years. The team swabbed the posterior nasopharynx prior to autopsy and at autopsy they collected lung, liver, and, when possible, cerebrospinal fluid for mycobacterial culture and histopathology.

The team assessed the diagnostic performance of Xpert MTB/RIF Ultra (Ultra; Cepheid, Sunnyvale, CA, USA) on nasopharyngeal specimens collected post-mortem. Confirmed tuberculosis was defined as Mycobacterium tuberculosis complex (MTBc) recovery by culture with consistent tissue histopathology findings; decedents with only histopathology findings, including acid-fast staining or immunohistochemistry were defined as probable tuberculosis.

The investigators reported that TB was identified at autopsy in 27 (13.2%) decedents, of which 22 (81.5%) were confirmed and five (18.5%) were probable. Six (22.2%) decedents with TB were diagnosed by minimally invasive tissue sampling (MITS), all confirmed by MTBc culture. Nineteen (70.4%) of 27 decedents with confirmed or probable TB had MTBc detected by Ultra nasopharyngeal swab. The median (range) time interval from death to collection of nasopharyngeal swab for those with Ultra MTBc detection was 18 (7, 47) hours and 22 (4, 74) hours for all Ultra undetected, without significant difference. No rifampicin resistance was detected. The post-mortem Ultra approach showed sensitivity of 81.8% and specificity of 98.4% for confirmed TB diagnosis, with separate calculations for confirmed or probable TB diagnoses.

The authors concluded that the Ultra assay by nasopharyngeal swab collected post-mortem showed moderate sensitivity and high specificity for the diagnosis of fatal TB. For both in-hospital deaths and deaths in the community, the nasopharyngeal Ultra may provide an accessible tool for critical assessment of TB-associated mortality missed during clinical evaluation. Enhanced case detection using this approach would likely benefit national TB prevention efforts in high-burden settings. The study was published on March 27, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
Duke University
Cepheid 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.